Glass House BrandsGLAS 44 Debt-to-Equity is 0.42 as of Mar. 2026, which is 29% below its 10-year median of 0.59. GuruFocus rates GLAS with a GF Score™ of 44/100 and a GF Value™ of $6.46 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 809 Drug Manufacturers companies, Glass House Brands ranks worse than 63.29% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Glass House Brands's Debt-to-Equity or its related term are showing as below:
GLAS'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.02 Med: 0.59 Max: 1.93
Current: 0.42
During the past 6 years, the highest Debt-to-Equity Ratio of Glass House Brands was 1.93. The lowest was 0.02. And the median was 0.59.
GLAS's Debt-to-Equity is ranked worse than 63.29% of 809
companies
in the Drug Manufacturers industry
Industry Median: 0.27
vs GLAS: 0.42
Glass House Brands (NYSE:GLAS) Debt-to-Equity Explanation
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Glass House Brands Debt-to-Equity Related Terms
Glass House Brands Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Glass House Brands's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Glass House Brands's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Glass House Brands Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Glass House Brands's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Glass House Brands's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Glass House Brands (GLAS) has a Debt-to-Equity of 0.42 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Glass House Brands and its competitors. This is 29% below median its historical median of 0.59. Over the past decade, Glass House Brands' Debt-to-Equity has ranged from 0.02 to 1.93. According to the industry distribution chart, Glass House Brands ranks #512 out of 809 companies in the Drug Manufacturers industry, placing it in the top 63.3%.
Is Glass House Brands' Debt-to-Equity too high?
Glass House Brands' current Debt-to-Equity of 0.42 is 29% below median its 10-year median of 0.59. Over the past 10 years, this metric has ranged from a low of 0.02 to a high of 1.93. The Drug Manufacturers industry median Debt-to-Equity is 0.27. Glass House Brands' value of 0.42 is 55.6% above this industry median. Based on the distribution chart, Glass House Brands ranks #512 out of 809 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Glass House Brands has a GF Score™ of 44/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Glass House Brands' Debt-to-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Glass House Brands ranks #512 out of 809 companies for Debt-to-Equity. This places Glass House Brands in the lower half of its industry. The industry median Debt-to-Equity is 0.27. Glass House Brands' value of 0.42 is 55.6% above this benchmark. Historically, Glass House Brands' own Debt-to-Equity has ranged from 0.02 to 1.93 over the past decade. While the company's 10-year median is 0.59 vs. the industry median of 0.27, Glass House Brands has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.27, based on 809 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Glass House Brands's current Debt-to-Equity of 0.42 is 55.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Glass House Brands and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Glass House Brands's current Debt-to-Equity is 0.42, which is 29% below median its own 10-year median of 0.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Glass House Brands stock overvalued right now?
Based on GuruFocus' analysis, Glass House Brands (GLAS) is currently considered Significantly Overvalued. The stock's GF Value™ is $6.46, compared to a current price of $13.00 — trading 101.2% above its estimated fair value. The current Debt-to-Equity is 0.42, which is 29% below median its 10-year median of 0.59 and 55.6% above the Drug Manufacturers industry median of 0.27. Glass House Brands' overall GF Score™ is 44/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Glass House Brands (GLAS), the current Debt-to-Equity is 0.42 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Glass House Brands (GLAS) Overvalued in 2026?
Based on GuruFocus' analysis, Glass House Brands stock appears to be overvalued.
The current stock price of $13.00 is trading 101.2% above its estimated GF Value™ of $6.46.
GuruFocus considers Glass House Brands to be Significantly Overvalued.
Key valuation signals for GLAS:
Debt-to-Equity: 0.42 (29% below median its 10-year median of 0.59)
GF Value™: $6.46 vs. price of $13.00 (101.2% above fair value)
Industry Position: 55.6% above the Drug Manufacturers median (#512 of 809)
No single metric tells the full story. See the GLAS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Glass House Brands Inc is an integrated cannabis company that operates exclusively in the state of California. Its portfolio of brands includes Glass House Farms, Forbidden Flowers, and Mama Sue Wellness. It cultivates, manufactures, and distributes cannabis bulk flower and trim to wholesalers and consumer packaged goods to third-party retail stores. It also owns and operates retail cannabis stores in the state of California. It has three reportable segments: Retail, Wholesale Biomass, and Cannabis-related consumer packaged goods. It generates the majority of its revenue from the Wholesale Biomass segment.
44GF Score
Get the complete analysis for GLAS
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GLAS has been successfully added to your 
